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Clash of giants: relative complexity of metabolic 
pathways and genomes
There  are  approximately  ten  times  as  many  expressed 
genes (proteins) as there are different metabolites in most 
cells. Biochemical analysis of cells has been the art of the 
possible;  you  know  about  what  you  can  detect.  In  the 
past, assays have largely focused on small organic (bio)
molecules analyzed by colorimetry or spectrophotometry. 
The genome projects have revealed a completely different 
data  set  from  that  of  classical  metabolic  biochemistry, 
and a totally different perspective on metabolism. Two 
different perspectives, as neatly presented by Gerrard et 
al. [1], are presented in Figure 1; note how the genome 
draws  attention  to  the  proteins,  many  of  which  are 
enzymes, but many of which are not. So, measuring the 
concentrations  of  metabolites  as  we  do  in  clinical 
biochemistry  only  indirectly  reports  on  which  of  the 
enzymes, control proteins, or structural proteins are at 
fault in a case of chemical poisoning, drug side-effects, or 
in an inborn error of metabolism.
Figure  2  reminds  us  that  there  are  at  least  5,000 
different enzymes, with as many metabolites in pathways 
that interconvert molecules in well-ordered sequences of 
reactions in an ‘average’ human cell. Figure 3 emphasizes 
that  any  one  metabolite  (denoted  γ  in  this  case)  can 
modulate reactions from within its own pathway, across 
pathways, and even alters expression of genes and trans-
lation of messenger RNA into protein. An enzyme can 
also serve to modulate the activity of another enzyme, 
and affect its level of expression. Cations, including H+, 
and  extraneous  compounds  such  as  xenobiotics  (H  in 
Figure 3), also exert effects on enzymes and metabolites 
that potentially affect fluxes through multiple pathways.
Traditional clinical biochemistry versus 
metabolomics
A  modern  and  emerging  form  of  advanced  diagnostic 
strategy  in  chemical  pathology  is  metabolomics,  also 
called metabonomics [2]. There is a semantic and opera-
tional difference between these ‘omics’. The former is the 
study of an extensive collection of metabolites present in 
a cell or tissue under a particular set of conditions (the 
metabolome) generating a biochemical profile. The latter 
involves the same profiling but in response to an influ-
ence (drug, toxin, or genetic defect) and then prediction 
of metabolic pathway(s) for the process(es). The approaches 
adopt an overview strategy that is superficially described 
as ‘fingerprinting’. The investigator does not need to have 
a  preconceived  notion  of  what  the  metabolic  problem 
might  be  with  a  patient  because  the  methodology  is 
Abstract
The metabolic syndrome, inborn errors of metabolism, 
and drug-induced changes to metabolic states all bring 
about a seemingly bewildering array of alterations 
in metabolite concentrations; these often occur in 
tissues and cells that are distant from those containing 
the primary biochemical lesion. How is it possible 
to collect sufficient biochemical information from a 
patient to enable us to work backwards and pinpoint 
the primary lesion, and possibly treat it in this whole 
human metabolic network? Potential analyses have 
benefited from modern methods such as ultra-high-
pressure liquid chromatography, mass spectrometry, 
nuclear magnetic resonance spectroscopy, and more. 
A yet greater challenge is the prediction of outcomes 
of possible modern therapies using drugs and genetic 
engineering. This exposes the notion of viewing 
metabolism from a completely different perspective, 
with focus on the enzymes, regulators, and structural 
elements that are encoded by genes that specify 
the amino acid sequences, and hence encode the 
various interactions, be they regulatory or catalytic. The 
mainstream view of metabolism is being challenged, 
so we discuss here the reconciling of traditionally 
quantitative chemocentric metabolism with the 
seemingly ‘parameter-free’ genomic description, and 
vice versa.
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© 2010 BioMed Central Ltdnon-selective for particular metabolites, and yet speci-
fically detects a broad range of them. In contrast, what 
has traditionally been done in clinical biochemistry is to 
work with a diagnostic hypothesis because only a limited 
set of tests exists to apply to a patient’s blood, or biopsy 
tissue, to help make a diagnosis. So focus is placed on a 
biochemical  system;  if  the  test  points  in  a  particular 
direction of enquiry, then another test is ordered, and so 
forth. Not so with the metabol(n)omics ‘shotgun’ approach!
Now that genes can be inserted into cells to correct 
metabolic defects in animals (for example, [3]), and pre-
su  mably ultimately in humans, it will be important to be 
able to predict and monitor the metabolic consequences 
of  these  genetic  manipulations,  thus  bringing  together 
the  two  paradigms:  namely  delineating  metabolism  by 
perturbing  it  with  small  molecules  such  as  toxins  and 
drugs, and perturbing it by manipulating gene expression, 
thus affecting enzyme activities.
To elaborate on the previous point, ‘Will the insertion 
of a “good” gene into a baby who has inherited a defective 
gene  lead  to  them  having  a  normal  life?’  On  contem-
plating this point, it becomes obvious that: (1) the gene 
must  be  able  to  be  targeted  to  those  tissues  where  it 
usually functions; (2) it must be delivered in sufficient 
quan  ti  ties  to  transform  a  large  enough  fraction  of  the 
cells  in  the  tissues  to  a  normal  state  with  normal 
Figure 1. Two different ways of representing metabolic pathways. (a) The ‘old view’ in which the metabolites hold ‘center stage’. The names 
of enzymes (in yellow boxes) are written above reaction arrows that show the chemical transformation of reactants (red circles; representing one 
or more co-reactants) to new metabolites. These can often be detected, characterized, and quantified by physical and chemical techniques, most 
notably in recent years by mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. (b) The modern ‘genome-centric view’ of 
metabolism in which the enzymes (gene products themselves) hold ‘center stage’. Note that the metabolic pathway is represented as a string of 
enzymes (E1 to En), with the metabolites entering and leaving above the arrows. The tools of genomics include the polymerase chain reaction (PCR) 
for gene amplification and thence sequencing, and identification of the code with that of a particular protein, and DNA sequencing, which makes 
genome-genome comparisons almost commonplace.
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Page 2 of 8responses to nervous and endocrine ‘cues’; and (3) ‘What 
if  only  a  small  fraction  of  the  cells  were  transformed? 
What  is  the  minimum  fraction  that  would  lead  to 
“rescuing” the metabolic state of the whole organ(s) and 
hence the individual?’
Quantitative prediction of metabolic responses
How do we begin to predict the metabolic responses to 
experi  mental  genetic  manipulations  in  something  as 
chemically complex as a baby (or even a mouse), when 
we struggle to describe metabolism in quantitative terms 
for even the simplest of cells, notably erythrocytes (for 
example, [4-10])?  To  give  an  impression  of  the  task  at 
hand,  consider  glycolysis  and  the  pentose  phosphate 
pathway of the human erythrocyte (Figure 4a): there are 
approximately  25  enzymes  involved  (but  there  are  as 
many, again, doing other things, not included here, such 
as peptidases, phospholipases, catalase, carbonic anhydrase, 
and  so  on),  and  hexokinase,  the  first  enzyme  in  the 
pathway, has the level of details shown in Figure 4b to 
account  for  its  reaction  rate  as  a  function  of  the  con-
centration of substrates, products and effectors, including 
H+! In order to account for the exquisite pH dependence 
of  the  steady-state  concentration  of  2,3-bisphos-
phoglycerate, the pH dependence of all the key reactions 
(enzymes) needed to be incorporated into the expressions 
for the various equilibrium and kinetic constants. Only 
then was it possible to analyze the mathematical model 
to identify the fact that H+ ions exerted their effect on the 
concentration  of  2,3-bisphosphoglycerate  mostly  via 
three different enzymes, two of which are far removed in 
the  pathway.  Such  is  the  behavior  of  a  system  that  in 
Figure 2. Representation of the enzyme-centric view of metabolism. The horizontal rows of arrows represent the various groups of enzymes 
that are associated with the systematic changing of an input metabolite(s) to an end product, be it a fuel, an effector/controller of another reaction, 
or a building block for a biopolymer, such as protein or nucleic acid. The vertical green arrows denote the gene-to-messenger RNA-to-protein 
sequence of reactions that occur for the approximately 5,000 different enzymes of human metabolism.
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made possible by performing a type of meta-analysis on 
the  model  using  the  guiding  principles  of  metabolic 
control analysis [11] and especially the important idea of 
co-response  coefficients  [12,13].  In  other  words,  having 
done  an  experimental  study  of  a  metabolic  system,  a 
mathematical  model  consisting  of  rate  equations  is 
formulated;  and  the  simulations  are  used  to  test 
hypotheses that relate to control of the reaction network. 
This  abstraction  is  then  used  to  inform  further 
experiments on the real system, and so forth, in a series of 
iterative  loops  between  numerical  simulation  and  real 
experiment, thus refining understanding of the real system.
Metabolic processes in unicellular organisms such as 
bacteria and yeast have been studied using this approach, 
but  they  turn  out  to  be  even  more  complex  than  the 
human  erythrocyte.  This  is  because  they  have  the  full 
complement of metabolic machinery that is required to 
maintain  an  autonomous  existence  and  to  reproduce 
themselves; the human (mammalian) erythrocyte is an 
end-stage  differentiated  cell  and  thus,  while  relatively 
simpler, it is still complex. The human erythrocyte has 
been subjected to the most detailed biochemical analysis 
and computer modeling of all known cell types, and has 
been  a  fruitful  guide  to  the  future  of  metabolic 
simulations  and  quantitative  analysis  of  metabolic 
Figure 3. Reminder of the complexity of the control of the activity of an enzyme. In the bottom metabolic pathway, the generic metabolite 
γ can be: (a) a positive- or negative-feedback effector of the generic enzyme E5000; (b) a positive- or negative-feedforward effector of the generic 
enzyme E5000+k; (c) a product inhibitor or homotropic effector of the enzyme that catalyzes its production; (d) a positive or negative effector of an 
enzyme that catalyzes a chemically ‘distant’ (unrelated, non-precursor chemical structures) reaction in another pathway’; and (e) a product affecting 
the transcription of a gene and/or its translation to a mature enzyme that is properly transferred to its ‘correct’ cellular compartment. The generic 
enzyme E100 affects other reactions: (f) by protein-protein interactions, as a macromolecular effector; and (g) through entry into the nucleus and 
affecting DNA transcription, or, in the cytoplasm, messenger RNA translation into protein. External effectors (H), such as H+ ions, hormones, or 
xenobiotics, can interact with one of more enzymes and metabolites to influence the flux through one or more metabolic pathways.
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most of the concepts that will be necessary to scale up to 
a model of the whole human metabolic network.
Computer models of metabolism
It  is  intriguing  that  the  first  serious  attempts  to  model 
metabolism  in  cells  considered  yeast,  hepatocytes,  and 
myocytes,  and  the  models  began  with  a  high  level  of 
complexity.  Consideration  was  given  to  the  detailed 
mechanisms of the individual enzymes in many metabolic 
pathways, such as those shown in stylized form in Figure 
1a,  with  control  of  enzymes  by  small  molecules  as  is 
represented in Figure 3. Such work was exemplified by that 
of Britton Chance, Edwin Chance and Joseph Higgins, and 
later by that of David and Lillian Garfinkel and colleagues 
[14]. As it was obvious 40 years ago, and is even more 
apparent  today,  it  is  difficult  to  obtain  the  coherent/
consistent sets of data required to guide the development 
of quantitative models of metabolism in a particular tissue 
[7-9]. Future developments will need some, and more, of 
the blanket approaches to identify and quantify meta  bo-
lites  that  have  been  used  in  metabol(n)omics,  such  as 
chromatographic  methods  linked  to  mass  spectrometry 
and nuclear magnetic reso  nance spectro  scopy [15,16]; also 
called ‘hyphenated modalities’ .
Those interested in optimizing batch cultures of micro-
organisms  for  the  industrial  production  of  substances 
such as antibiotics, or even simple ethanol, have adopted 
a  more  phenomenological  approach  to  their  models 
[17,18]; in other words, an attempt is made to represent 
Figure 4. Human erythrocyte metabolism modeled using detailed enzyme rate equations. The enzyme rate equations are described in [10]. 
(a) The reaction scheme for the glycolytic pathway, and (b) the first rate equation used in the model of the glycolytic pathway for hexokinase; many 
of the other enzyme rate equations are of similar complexity to this.
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detailed underlying mechanism for each enzymic reac-
tion. While some of these models of metabolism are very 
complicated,  they  do  not  (generally)  involve  the  fine 
details of pre-steady-state or even steady-state rate equa-
tions for the respective enzymes. The set of simultaneous 
linear and non-linear differential equations that consti-
tute  deterministic  models  can  be  investigated  using  a 
form of sensitivity analysis (developed in the 1960s by 
chemical  engineers  [19],  and  now  a  part  of  metabolic 
control  analysis  [11])  to  help  identify  flux-controlling 
steps (enzymes) that then become the target for genetic 
manipulations of the organism [5].
The  main  proponent  of  large-scale  modeling  of 
metabolism is Professor Bernhard Palsson and his team at 
the University of California, San Diego, California, USA. 
Their  work  to  date  has  largely  been  phenomeno  logical 
and can be classified as ‘biochemical engineering’; it is of a 
kind  that  also  attracted  attention  to  the  late  Professor 
James  Bailey,  who  nevertheless  recognized  the  need  to 
consider genomics in formulating the next generation of 
metabolic models [20]. The emphasis is on process output 
and  the  amount  of  detail  used,  as  in  pragmatic 
engineering,  is  just  sufficient  for  describing  the  bio-
processing task in hand. The models are funda  men  tally 
different from those that biochemists have con  structed of 
human erythrocyte metabolism [7-10]. However, in the 
process of setting up their massive databases, Palsson and 
colleagues  have  established  a  means  of  storing  infor-
mation relating to vast arrays of individual enzymes. This 
‘library’ system could, in principle, contain, and be used to 
curate, all the data compiled in any other highly enzyme-
mechanism-based  model;  indeed,  they  have  already 
subsumed some of the more mechanistic equations from 
other models, such as in [6].
Thus,  the  large-scale  and  very  ambitious  projects  in 
metabolic  modeling  have  identified  the  need  to  curate 
data from disparate sources and make it available to one 
model.  Palsson’s  team  recently  listed  45  bacteria,  2 
archaea,  and  11  eukaryotes,  including  Homo  sapiens, 
among those with detailed models of metabolism in their 
database  [21].  To  obtain  some  idea  of  the  complexity 
involved, consider Bacillus subtilis: there are 4,114 genes 
that  express  1,103  enzymes/proteins  involved  in  1,437 
reactions with 1,138 metabolites [21,22]. Keeping track of 
the  metabolites  and  the  reaction  kinetics  with  experi-
mental  data  to  justify  particular  choices  of  parameter 
values  demands  elegant  file-handling  programs  and 
powerful computers.
The process of setting up the differential rate equations 
that  are  solved  to  predict  time  courses  of  metabolism 
under various conditions rests on a central idea that is 
well described in the book by Heinrich and Schuster [11], 
namely  the  stoichiometry  matrix,  and  it  has  been 
implemented  in  other  well-known  programs  (for 
example, [23], and also in [10]). This is a mathematical 
con  struct  that  has  a  list  of  reaction  names  (enzyme 
names)  in  the  metabolic  system  across  the  top  of  the 
columns  of  the  matrix.  The  matrix  is  often  gigantic, 
having as many columns as there are enzymes, and the 
metabolite names (reactants), which can number in the 
thousands,  down  the  rows.  Automatic  writing  of  the 
differential  equations  that  describe  the  rates  of  the 
biochemical reactions is done by the computer program 
(for example, [21]; this has also been done, on a smaller 
scale, in Mathematica [10]); the process involves access-
ing a separate list (the velocity vector) of rate equations 
that contains the kinetic descriptions of each reaction, 
either at the level of steady-state kinetics - for example, 
the  Michaelis-Menten  equation  -  or  represented  as 
simple first and second order rate equations where the 
enzyme concentration is implicit in the value of a rate 
constant. Thus, there are as many differential rate equa-
tions as there are metabolites. In other words, the model 
can engulf all previous estimates of metabolite concen-
trations and enzyme kinetic data relevant to the meta-
bolic pathway under consideration.
The  massive  library  of  metabolic  information,  orga-
nized around the velocity and substrate vectors and the 
stoichiometry  matrix,  can  readily  be  expanded  to 
incorporate control networks, such as hormone effects 
(for  example,  [17]).  However,  a  major  question  that 
emerges  from  combining  all  these  data  is  how  do 
conflicts  between  disparate  data  sets,  from  different 
investigations/investigators with different techniques, get 
resolved?  The  problem  has  not  been  systematically 
resolved  and  has  been  left  to  individuals  to  do  the 
filtering of the data (for example, [24]).
A coarser grained view
The major effort in quantitative holistic human modeling 
is  the  Human  Physiome  Project  [25].  The  Human 
Physiome  Project  runs  under  the  aegis  of  the  Inter-
national  Union  of  Physiological  Societies,  and  the 
Institute of Electronic and Electrical Engineers’ Engineer-
ing in Medicine and Biology Society, and it was made the 
main focus of the International Union of Physiological 
Societies  for  the  decade  commencing  in  1993,  and  it 
continues  today  [26];  but  the  temporal  and  structural 
scales have not been those of metabolism - they are more 
those  of  tissue/anatomical  structure.  The  Human 
Physiome Project is divided into 12 major systems, with 
the heart and cardiovascular system appearing to attract 
most attention (for example, [27,28]). The blood in this 
system  (hematopoietic  tissue  plus  circulating  erythro-
cytes; also called the erythron) constitutes approximately 
6 kg of the average adult mass (8.6%), with the approxi-
mately 2 kg of erythrocytes visiting all tissues, being a 
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and intracellular glutathione; and blood is also the main 
vehicle  for  the  distribution  (and  degradation)  of 
hormones. A model of the blood should be a key aspect 
of the quantitative human physiome; it will tie all the 12 
systems together, with hormone signaling, nutrient and 
O2 delivery, and metabolite and CO2 disposal, as relevant 
to all tissues. On the other hand, there appear to be few 
signs that models of human erythrocyte metabolism are 
about to be included in the Human Physiome Project; so 
inclusion of the much more complex metabolic models of 
Palsson  et  al.  (for  example,  [21,22])  into  the  Human 
Physiome Project appears remote at this juncture.
Metabonomics and its challenges
A  recent  application  of  metabonomics  has  been  in 
experimental  pancreatitis  in  animals  in  which  major 
changes  in  blood  chemistry  are  seen  in  response  to 
arginine overloading. The interpretation of the metabolic 
profiles is based on known biochemical pathways, and 
yet the interpretation is still only qualitative. Never  the-
less,  the  work  appears  to  lend  itself  to  quantitative 
metabolic modeling, which could make predictions more 
robust before it is applied to humans [29]. In spite of the 
huge  amount  of  biochemical  information  available  in 
such studies, much more information is required to make 
an enzyme-mechanistic model of the system of the kind 
developed for the human erythrocyte [7-10].
Complicating issues
Thus far we have considered straightforward comparisons 
between standard enzyme kinetics and the prediction of 
metabolic responses. However, it is well known that some 
reactions inside cells do not follow the kinetics predicted 
from  studies  in  vitro.  One  of  the  hopes  for  magnetic 
resonance spectroscopy is to study the kinetics of reac-
tions as they occur in situ in cells or tissues. A compli-
cation  that  arises  in  situ  is  metabolite/substrate 
channeling, and yet the only model to date that has been 
based  on  real  experimental  data  is  that  of  arginine 
channeling in the urea cycle of isolated rat hepatocytes 
[30]. How much more complicated would be the kinetic 
characterization of metabolite channeling in the human 
liver in vivo?
One way to begin to look more closely at the flux of 
carbon atoms in metabolites through intersecting meta-
bolic modules is to use  13C nuclear magnetic resonance 
isotopomer  analysis  (for  example,  [31]).  The  ensuing 
increase in computational complexity brought about by 
the requirement to keep track of all combinations of 13C 
labels  in  isotopomers  has  seen  this  area  of  computer 
modeling  move  very  slowly.  Nevertheless,  the  recent 
example  of  B.  subtilis  metabolism  is  an  important 
advance [22]. And there is another subtlety: not all sites 
in an end product of a metabolite may ever be labeled 
because of the particular subset of combinatorial shuf-
fling of carbon atoms at different positions in a metabolite 
in a cell type. This realization both compli  cates possible 
experimental  interpretations  and  could  also  serve  as  a 
type  of  diagnostic  test,  identifying  which  of  a  set  of 
possible reactions are in operation in a tissue or cell type 
in a given time interval [32].
Conclusions
It  appears  that  the  methods  of  metabol(n)omics  that 
generate massive data sets on metabolite concentrations 
might  tempt  speculation  that  a  detailed  quantitative 
predictive model of the whole human metabolic network 
is imminent. On the other side of the ‘conceptual divide’, 
modelers of complicated metabolism, who have solved 
the  problem  of  data  curation,  and  fast  and  accurate 
numerical integration of differential rate equations, imply 
that the ‘all that is needed are some data’; their methods 
are ready, waiting, and up to the task. Unfortunately, even 
modeling  the  metabolism  of  the  simplest  mammalian 
cell,  the  erythrocyte,  has  and  still  does  require  pain-
staking experimental analysis by a range of techniques; 
the latest addition in this area (on glutathione synthesis) 
was 6 years in the making [24]!
In  conclusion,  it  would  be  demoralizing  to  base  our 
predictions of a date when the whole human metabolic 
network would be complete on present technology. What 
is needed is the counterpart of the sort of breakthrough 
in technology that saw the Human Genome Project reach 
fruition  ‘from  left  field’  via  shotgun  DNA  sequencing, 
which is utterly reliant on massive computer power. It 
appears that, in the present case, we have the computing 
power and methods, but what we lack are the techniques 
of  metabolite  analysis,  and  various  means  of  rapidly 
recording protein-protein and ligand-protein inter  actions. 
Furthermore, the genome-centric view of metabolism is 
identifying new modes of metabolic regulation, such as 
the indirect effects of interfering RNAs, and these will 
need to be incorporated in models of metabolism and its 
control.  Therefore,  there  is  much  to  be  done  before 
computer models of metabolism form part of the suite of 
methods used in clinical management.
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